Mast cell activation in vivo impairs the macrophage reverse cholesterol transport pathway in the mouse

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 3, 2011, Pages 520-527

  Lee Rueckert, Miriam ^a   Silvennoinen, Reija ^a   Rotllan, Noemi ^b   Judström, Ilona ^a   Blanco Vaca, Francisco ^b,c,d   Metso, Jari ^e   Jauhiainen, Matti ^e   Kovanen, Petri T ^a   Escola Gil, Joan Carles ^b,c  

^a WIHURI RESEARCH INSTITUTE   (Finland)

^b BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

apolipoprotein A I; cholesterol efflux; macrophages; mast cell chymase; reverse cholesterol transport

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL; CHYMASE; MAST CELL DEGRANULATING PEPTIDE; STEM CELL FACTOR; TRITIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ACTIVATION; CELL CULTURE; CELL LABELING; CELL VACUOLE; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; FEMALE; IN VIVO STUDY; INTESTINE; MACROPHAGE; MOUSE; NONHUMAN; PERITONEAL CAVITY; PERITONEAL FLUID; PERITONEUM MAST CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; RADIOACTIVITY; STOMACH JUICE; WILD TYPE;

ANIMALS; APOLIPOPROTEIN A-I; BIOLOGICAL TRANSPORT; CELL COMMUNICATION; CELL DEGRANULATION; CELL LINE; CHOLESTEROL; CHYMASES; FECES; FOAM CELLS; HUMANS; INJECTIONS, INTRAPERITONEAL; MACROPHAGES; MAST CELLS; MICE; MICE, INBRED C57BL; MUTATION; P-METHOXY-N-METHYLPHENETHYLAMINE; PHOSPHOLIPIDS; PROTEIN DENATURATION; PROTO-ONCOGENE PROTEINS C-KIT; TIME FACTORS; TRITIUM;

EID: 79952189374     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.221069     Document Type: Article

References (37)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340:115-126.
2. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res. 1995;36:211-228.
3. Cuchel M, Rader DJ. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation. 2006;113:2548-2555.
4. Marcel YL, Kiss RS. Structure-function relationships of apolipoprotein A-I: a flexible protein with dynamic lipid associations. Curr Opin Lipidol. 2003;14:151-157. (Pubitemid 36521185)
5. Alexander ET, Vedhachalam C, Sankaranarayanan S, de lL-M, Rothblat GH, Rader DJ, Phillips MC. Influence of apolipoprotein A-I domain structure on macrophage reverse cholesterol transport in mice. Arterioscler Thromb Vasc Biol. 2010. [Epub ahead of print].
6. Scanu AM, Edelstein C. HDL: bridging past and present with a look at the future. FASEB J. 2008;22:4044-4054.
7. Pejler G, Ronnberg E, Waern I, Wernersson S. Mast cell proteases: multifaceted regulators of inflammatory disease. Blood. 2010;115: 4981-4990.
8. Kaartinen M, Penttilä A, Kovanen PT. Extracellular mast cell granules carry apolipoprotein B-100-containing lipoproteins into phagocytes in human arterial intima: functional coupling of exocytosis and phagocytosis in neighboring cells. Arterioscler Thromb Vas Biol. 1995;15:2047-2054.
9. Lee-Rueckert M, Kovanen PT. Mast cell proteases: physiological tools to study functional significance of high density lipoproteins in the initiation of reverse cholesterol transport. Atherosclerosis. 2006;189:8-18. (Pubitemid 44441294)
10. Judstrom I, Jukkola H, Metso J, Jauhiainen M, Kovanen PT, Lee-Rueckert M. Mast cell-dependent proteolytic modification of HDL particles during anaphylactic shock in the mouse reduces their ability to induce cholesterol efflux from macrophage foam cells ex vivo. Atherosclerosis. 2010;208:148-154.
11. Pejler G, Abrink M, Ringvall M, Wernersson S. Mast cell proteases. Adv Immunol. 2007;95:167-255. (Pubitemid 47380506)
12. Lindstedt L, Lee M, Kovanen PT. Chymase bound to heparin is resistant to its natural inhibitors and capable of proteolyzing high density lipoproteins in aortic intimal fluid. Atherosclerosis. 2001;155:87-97. (Pubitemid 32167128)
13. Eriksson M, Carlson LA, Miettinen TA, Angelin B. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I: potential reverse cholesterol transport. Circulation. 1999;100:594-598.
14. Nanjee MN, Cooke CJ, Garvin R, Semeria F, Lewis G, Olszewski WL, Miller NE. Intravenous apoA-I/lecithin discs increase pre-β-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J Lipid Res. 2001;42:1586-1593. (Pubitemid 33020090)
15. Zhang Y, Zanotti I, Reilly MP, Glick JM, Rothblat GH, Rader DJ. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation. 2003;108: 661-663. (Pubitemid 36999247)
16. Alexander ET, Weibel GL, Joshi MR, Vedhachalam C, de la Llera-Moya M, Rothblat GH, Phillips MC, Rader DJ. Macrophage reverse cholesterol transport in mice expressing ApoA-I Milano. Arterioscler Thromb Vasc Biol. 2009;29:1496-1501.
17. Lee-Rueckert M, Vikstedt R, Metso J, Jauhiainen M, Kovanen PT. Association of cholesteryl ester transfer protein with HDL particles reduces its proteolytic inactivation by mast cell chymase. J Lipid Res. 2008;49: 358-368. (Pubitemid 351213620)
18. Langmann T, Klucken J, Reil M, Liebisch G, Luciani M-F, Chimini G, Kaminski WE, Schmitz G. Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1): evidence of sterol-dependent regulation in macrophages. Biochem Biophys Res Commun. 1999;257:29-33. (Pubitemid 29299042)
19. Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res. 2009;50(suppl):S189-S194.
20. Escola-Gil JC, Rotllan N, Julve J, Blanco-Vaca F. In vivo macrophage-specific RCT and antioxidant and antiinflammatory HDL activity measurements: new tools for predicting HDL atheroprotection. Atherosclerosis. 2009;206:321-327.
21. Calpe-Berdiel L, Rotllan N, Fievet C, Roig R, Blanco-Vaca F, Escola-Gil JC. Liver X receptor-mediated activation of reverse cholesterol transport from macrophages to feces in vivo requires ABCG5/G8. J Lipid Res. 2008;49:1904-1911.
22. Naik SU, Wang X, Da Silva JS, Jaye M, Macphee CH, Reilly MP, Billheimer JT, Rothblat GH, Rader DJ. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation. 2006;113:90-97. (Pubitemid 43958493)
23. Rotllan N, Ribas V, Calpe-Berdiel L, Martin-Campos JM, Blanco-Vaca F, Escola-Gil JC. Overexpression of human apolipoprotein A-II in transgenic mice does not impair macrophage-specific reverse cholesterol transport in vivo. Arterioscler Thromb Vasc Biol. 2005;25:e128-e132.
24. Zhang Y, Da Silva JR, Reilly M, Billheimer JT, Rothblat GH, Rader DJ. Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. J Clin Invest. 2005;115:2870-2874. (Pubitemid 41434414)
25. Rodrigueza WV, Williams KJ, Rothblat GH, Phillips MC. Remodelling and shuttling: mechanism for the synergistic effects between different acceptor particles in the mobilization of cellular cholesterol. Arterioscler Thromb Vasc Biol. 1997;17:383-393. (Pubitemid 27098198)
26. Curtiss LK, Valenta DT, Hime NJ, Rye KA. What is so special about apolipoprotein AI in reverse cholesterol transport? Arterioscler Thromb Vasc Biol. 2006;26:12-19.
27. Chau P, Nakamura Y, Fielding CJ, Fielding PE. Mechanism of pre-β-HDL formation and activation. Biochemistry. 2006;45:3981-3987.
28. Vedhachalam C, Duong PT, Nickel M, Nguyen D, Dhanasekaran P, Saito H, Rothblat GH, Lund-Katz S, Phillips MC. Mechanism of ATP-binding cassette transporter A1-mediated cellular lipid efflux to apolipoprotein A-I and formation of high density lipoprotein particles. J Biol Chem. 2007;282:25123-25130. (Pubitemid 47347535)
29. Mulya A, Lee JY, Gebre AK, Thomas MJ, Colvin PL, Parks JS. Minimal lipidation of pre-β HDL by ABCA1 results in reduced ability to interact with ABCA1. Arterioscler Thromb Vasc Biol. 2007;27:1828-1836. (Pubitemid 47207180)
30. Lee JY, Lanningham-Foster L, Boudyguina EY, Smith TL, Young ER, Colvin PL, Thomas MJ, Parks JS. Pre-β high density lipoprotein has two metabolic fates in human apolipoprotein A-I transgenic mice. J Lipid Res. 2004;45:716-728. (Pubitemid 38405678)
31. Mulya A, Lee JY, Gebre AK, Boudyguina EY, Chung SK, Smith TL, Colvin PL, Jiang XC, Parks JS. Initial interaction of apoA-I with ABCA1 impacts in vivo metabolic fate of nascent HDL. J Lipid Res. 2008;49: 2390-2401.
32. Duong PT, Weibel GL, Lund-Katz S, Rothblat GH, Phillips MC. Characterization and properties of pre -HDL particles formed by ABCA1-mediated cellular lipid efflux to apoA-I. J Lipid Res. 2008;49:1006-1014.
33. Lee M, von Eckardstein A, Lindstedt L, Assmann G, Kovanen PT. Depletion of pre-1LpA1 and LpA4 particles by mast cell chymase reduces cholesterol efflux from macrophage foam cells induced by plasma. Arterioscler Thromb Vasc Biol. 1999;19:1066-1074.
34. Kokkonen JO. Stimulation of rat peritoneal mast cells enhances uptake of low density lipoproteins by rat peritoneal macrophages in vivo. Atherosclerosis. 1989;79:213-223. (Pubitemid 19226330)
35. Eberini I, Gianazza E, Breghi L, Klugmann S, Calabresi L, Gomaraschi M, Mombelli G, Brusoni B, Wait R, Sirtori CR. Apolipoprotein A-I breakdown is induced by thrombolysis in coronary patients. Ann Med. 2007;39:306-311. (Pubitemid 46897663)
36. Ndao M, Spithill TW, Caffrey R, Li H, Podust VN, Perichon R, Santamaria C, Ache A, Duncan M, Powell MR, Ward BJ. Identification of novel diagnostic serum biomarkers for Chagas' disease in asymptomatic subjects by mass spectrometric profiling. J Clin Microbiol. 2010;48: 1139-1149.
37. Lee M, Calabresi L, Chiesa G, Franceschini G, Kovanen PT. Mast cell chymase degrades apolipoprotein E and apoA-II in apoA-I-knockout mouse plasma and reduces its ability to promote cellular cholesterol efflux. Arterioscler Thromb Vasc Biol. 2002;22:1475-1481.